THURSDAY, July 17, 2025 (HealthDay News) — For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with an increased risk for gastroesophageal reflux disease (GERD) and its complications compared with sodium-glucose cotransporter-2 (SGLT-2) inhibitors, according to a study published online July 15 in the Annals of Internal Medicine. Yunha Noh, […]
The post GLP-1 Receptor Agonist Use in T2D Tied to Increased Risk for GERD, GERD Complications first appeared on Physician’s Weekly.
